Navigation Links
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
Date:4/17/2008

2, -1.9) (P=0.0003). In addition, a significantly greater proportion of patients treated with XP13512 (76.1 percent) was rated as responders on the CGI-I Scale compared to placebo (38.9 percent; P<0.0001).

Sleep disturbance is often associated with RLS. In this clinical trial, patients completed the Medical Outcomes Study (MOS) Sleep Scale to assess the impact of XP13512 treatment on sleep. At Week 12, XP13512-treated patients, compared to placebo-treated patients, had statistically significant improvements in sleep quantity and sleep adequacy, as well as statistically significant reductions in sleep disturbance and daytime somnolence.

The PIVOT RLS I clinical trial used a 24-hour diary to collect the presence and severity of RLS symptoms every 30 minutes starting at 8:00 a.m. At the end of the study, more than half of patients treated with XP13512 were symptom-free for the 24-hour assessment period compared to 18 percent of placebo-treated patients.

The two most commonly reported adverse events in the study were somnolence (27 percent, XP13512 vs. 7 percent, placebo) and dizziness (20 percent, XP13512 vs. 5 percent, placebo), with the majority reported as mild-to- moderate in intensity. Nine patients (8 percent) who received XP13512 withdrew from study participation due to adverse events compared to three patients (3 percent) who received placebo. No clinically meaningful changes in vital signs or laboratory parameters were observed.

In addition, the Epworth Sleepiness Scale (ESS), a reliable tool designed to measure daytime drowsiness, was used to evaluate the likelihood of patients dozing or falling asleep in common situations of daily living, such as sitting and reading or watching TV. At Week 12, the ESS scores for patients in the XP13512 group were lower than patients in the placebo group, indicating that XP13512 treatment was associated with less daytime drowsiness. The findings on the ESS scale are consistent with the reduction in
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- ResMed Inc. (NYSE: RMD ) today announced that ... June 30, 2015 results on Thursday, July 30, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)... July 2, 2015  The Green Exchange, Inc., the ... first HIPAA compliant mobile app that connects cannabis growers ... medical marijuana, announced today that their service provides the ... Meadow and more than half a dozen other delivery ... Loud Cannabis is unique in that it connects ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... , April 27, 2010 Shire plc (LSE: ... it has received a Paragraph IV Notice Letter from Anchen,Pharmaceuticals, ... Application ("ANDA") for a generic version of Shire,s 1 mg, ... tablets, INTUNIV(TM).,Shire had previously reported in March 2010 ...
... April 27 For a second consecutive year, following the ... Auto Thefts) is cautioning Michigan drivers, and now auto dealers ... theft-related crimes.   , , ... increased vehicle security features, and the continuing success of Michigan ...
Cached Medicine Technology:Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 2Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 3H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 2H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 3
(Date:7/4/2015)... ... July 04, 2015 , ... Earlier in 2015, on ... an annual member survey , detailing the most common plastic surgery and minimally ... that raw data down into charts detailing demographic trends and regional preferences. With ...
(Date:7/3/2015)... ... ... Bank will hopefully be getting a large donation of canned food items at the ... are making it their mission to collect as many canned items as possible. Donations do ... public as well. As part of the canned food drive, these local chiropractors will be ...
(Date:7/3/2015)... ... 2015 , ... Scientists at several top US cancer centers believe they now ... Click here to read the complete story , just posted on the Surviving ... Medical Center, and New York University exposed mice with a mutation on the tumor ...
(Date:7/3/2015)... ... 2015 , ... The Erie County Bar Association Institute of ... Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... these types of cases. , Each year, New York State residents are hospitalized ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency ... named Mariah N. Manzanares, MD as the new Medical Director of its Frisco facility. ... director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... 1,000 Reported Incidents, Caregivers Call for Comprehensive Process to Verify Signatures ... 31 Home care workers called for a hand-examination of each ... union, saying they had been subjected to lies, coercion, and fraud. ... the Service Employees International Union, United Healthcare Workers - West (SEIU-UHW), ...
... ... ... -- TDI, a leading provider of agent productivity solutions for contact centers, announced today that ... healthcare systems provider to the Greater New Orleans area. , , , , ,As an ...
... , , , ... HSP ), the world leader in generic injectable pharmaceuticals, today announced ... company,s applications for six new presentations of therapeutic heparin in single- ... to prevent clot formation in central venous catheters and for anticoagulant ...
... , , , CHADDS FORD, Pa., Aug. ... will present at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. ... Endo, will review the company,s products and development programs. , , ... website at www.endo.com under the investors section. ...
... , BERWYN, Pa., Aug. 31 Encorium ... clinical research organization (CRO) conducting studies in over 30 countries for ... that on August 25, 2009, it received a letter from The ... 10-Q for the period ended June 30, 2009, NASDAQ has determined ...
... , , , ... (the "Company") today announced that, at the Company,s 2009 Annual Meeting ... re-elect by an overwhelming majority all of the Company,s nominees to ... meeting were 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding ...
Cached Medicine News:Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:TDI Announces New Reseller Agreement With Executone 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: